Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.

Friday, July 25, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

BEDFORD, Mass., July 24 Hologic, Inc.(Nasdaq: HOLX) today announced the successful completion of the tender offerby its direct wholly-owned subsidiary, Thunder Tech Corp., for all outstandingshares of Third Wave Technologies, Inc. (Nasdaq: TWTI) at a price of $11.25per share in cash.

The subsequent offering period expired at 12:00 midnight, New York Citytime, on Wednesday, July 23, 2008. The initial tender offer period expired at12:00 midnight, New York City time, on Wednesday, July 16, 2008.

The depositary for the tender offer advised Hologic and the Purchaserthat, as of the expiration of the subsequent offering period, approximately47,968,050 shares were validly tendered and not withdrawn in the tender offer,representing approximately 95.8% of Third Wave's issued and outstandingshares. All validly tendered shares were accepted for payment in accordancewith the terms of the tender offer.

Hologic is in the process of completing the acquisition of Third Wavethough a short form merger in which Third Wave will become a wholly ownedsubsidiary of Hologic. In the short form merger, which will be completed assoon as practicable, all outstanding shares of Third Wave not purchased in thetender offer, and not held by a holder who demands appraisal rights for suchshares under the Delaware General Corporation Law, will be converted into theright to receive $11.25 per share in cash. Following the merger, detailedinstructions will be mailed to Third Wave stockholders who did not tendertheir shares in Third Wave in the offer outlining the steps to be taken toobtain the merger consideration. The effective date of the merger isanticipated to be July 24, 2008 and after the close of business on theeffective date, trading in Third Wave common stock on the NASDAQ will cease.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premiumdiagnostics, medical imaging systems and surgical products dedicated toserving the healthcare needs of women. Hologic's core business units arefocused on breast health, diagnostics, GYN surgical, and skeletal health.Hologic provides a comprehensive suite of technologies with products formammography and breast biopsy, radiation treatment for early-stage breastcancer, cervical cancer screening, treatment for menorrhagia, osteoporosisassessment, preterm birth risk assessment, and mini C-arm for extremityimaging. For more information visit http://www.hologic.com.

About Third Wave, Inc.

Third Wave develops and markets molecular diagnostic reagents for avariety of DNA and RNA analysis applications to meet the needs of itscustomers. Third Wave offers a number of products based on its Invader(R)chemistry for clinical testing. Third Wave offers in vitro diagnostic kits,and analyte specific, general purpose, and research use only reagents fornucleic acid analysis. For more information about Third Wave and its products,please visit Third Wave's website at http://www.twt.com.

Information Concerning Forward-Looking Statements

Information set forth in this communication contains forward-lookingstatements, which involve a number of risks and uncertainties. Suchforward-looking statements include, but are not limited to Hologic's plans,objectives, expectations and intentions and other statements that are nothistorical facts. Hologic cautions readers that any forward-lookinginformation is not a guarantee of future performance and actual results coulddiffer materially from those contained in the forward-looking information.

Risks and uncertainties include, among others: the risk that thebusinesses will not be integrated successfully; the transaction may involveunexpected costs or unexpected liabilities; the risk that the cost savings andany other synergies from the transaction may not be fully realized or may takelonger to realize than expected; disruption fr

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store